Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 5/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 10/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 10/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 10/20 | 0.46 |
| ▸ | HTR1A | P08908 | 7/20 | 0.46 |
| ▸ | HTR2C | P28335 | 3/20 | 0.42 |
| ▸ | USP25 | Q9UHP3 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23126972 | 0.88 | OPRL1 (0.40) | HTR6 | |
| SCHEMBL11366020 | 0.83 | NUDT1 (0.43) | HTR6 | |
| SCHEMBL26923285 | 0.81 | PANK3 (0.38) | HTR6 | |
| SCHEMBL22502738 | 0.81 | OPRL1 (0.45) | HTR6 | |
| SCHEMBL6709234 | 0.81 | TRPA1 (0.47) | HTR6SLC6A2SLC6A4SLC6A3HTR1A | |
| SCHEMBL11452948 | 0.81 | HTR6 (0.51) | HTR6SLC6A2SLC6A4SLC6A3HTR1A | |
| SCHEMBL22860585 | 0.79 | OPRL1 (0.46) | HTR6SLC6A2SLC6A4SLC6A3HTR2C | |
| SCHEMBL6709455 | 0.79 | HTR2C (0.59) | HTR6SLC6A2SLC6A4SLC6A3HTR1A | |
| SCHEMBL5937352 | 0.78 | HTR6 (0.48) | HTR6SLC6A2SLC6A4SLC6A3HTR1A | |
| SCHEMBL10266582 | 0.78 | SLC6A2 (0.58) | HTR6SLC6A2SLC6A4SLC6A3HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230062022-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | NUVATION BIO INC (US) | 2023-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230062022-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | CDK4, CDK6, CDK8 | HTR6 1501/4885SLC6A2 4801/4885SLC6A4 4672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.